In the Consumer Health segment, supply constraints in the United States (due to raw material availability and labor shortages), inflationary pressure and sales suspension of personal care products in Russia are likely to have continued to hurt sales. Zytiga, which already faces generic competition in the United States, lost exclusivity in EMEA markets in September, which is likely to hurt sales further in the fourth quarter. Generic/biosimilar competition for drugs like Zytiga, Procrit/Eprex and Remicade is likely to have hurt the top line. The Zacks Consensus Estimate for Imbruvica is $873 million, while our estimate is $849.7 million. Also, below pre-COVID levels in the CLL market are expected to have hurt sales in the United States and government clawbacks are expected to put pressure on sales in Europe. Rising competitive pressure in the United States from novel oral agents is likely to have hurt sales of the key drug, Imbruvica. However, lower sales of its key medicine, Imbruvica is likely to have hurt the top line in the fourth quarter. International sales are expected to have accounted for most of the COVID-19 vaccine sales. Its COVID-19 vaccine sales are expected to have been negligible in the fourth quarter. ![]() Other core products like Invega Sustenna and new drugs, Erleada and Tremfya, might have also contributed significantly to sales growth. The Zacks Consensus Estimate for Darzalex and Stelara is pegged at $2.07 billion and $2.46 billion, respectively while our estimates are $2.11 billion and $2.45 billion, respectively. J&J’s Pharma segment is expected to have contributed to the top line, led by increased penetration and market share gains of key products such as Darzalex and Stelara. Image Source: Zacks Investment Research Factors to Consider
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |